These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 11304502)

  • 21. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study.
    Tillin T; Orchard T; Malm A; Fuller J; Chaturvedi N
    J Hypertens; 2011 Jul; 29(7):1457-62. PubMed ID: 21602709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 24. Slowing progression along the renal disease continuum.
    Kopyt NP
    J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension and diabetes: epidemiologic aspects as a guide to management.
    Fuller JH
    J Cardiovasc Pharmacol; 1993; 21 Suppl 2():S63-6. PubMed ID: 7692153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular implications of albuminuria.
    Tuttle KR
    J Clin Hypertens (Greenwich); 2004 Nov; 6(11 Suppl 3):13-7. PubMed ID: 15538106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
    Donnelly R; Yeung JM; Manning G
    J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects?
    Haffner SM; Stern MP; Gruber MK; Hazuda HP; Mitchell BD; Patterson JK
    Arteriosclerosis; 1990; 10(5):727-31. PubMed ID: 2403300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988-2014.
    Sun X; Du T
    BMC Public Health; 2017 Nov; 17(1):893. PubMed ID: 29166886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of blood pressure control in the patient with diabetes.
    Bakris GL
    Am J Med; 2004 Mar; 116 Suppl 5A():30S-38S. PubMed ID: 15019861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension and diabetes: role of the renin-angiotensin system.
    Jandeleit-Dahm K; Cooper ME
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):469-90, vii. PubMed ID: 16959581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice.
    Volpe M
    Int J Clin Pract; 2008 Jan; 62(1):97-108. PubMed ID: 17971155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Particularities of hypertension in diabetic patient].
    Valensi P
    Rev Prat; 2004 Mar; 54(6):633-6. PubMed ID: 15222614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative stress in insulin-resistant conditions: cardiovascular implications.
    Stump CS; Clark SE; Sowers JR
    Treat Endocrinol; 2005; 4(6):343-51. PubMed ID: 16318400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension and the cardiometabolic syndrome.
    Manrique C; Lastra G; Whaley-Connell A; Sowers JR
    J Clin Hypertens (Greenwich); 2005 Aug; 7(8):471-6. PubMed ID: 16103758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When to treat the hypertensive diabetic patient.
    Fuller JH
    J Diabetes Complications; 1996; 10(3):144-5. PubMed ID: 8807461
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.